Confirming a new rise in albuminuria with repeat first-morning UACR

Diabetic Nephropathyhard

A 68-year-old man with CKD G3b, type 2 diabetes, and hypertension feels well. He exercises 4 days per week and follows a sodium-restricted diet. Medications are chlorthalidone, olmesartan, dapagliflozin, and metformin. BP is 114/62 mm Hg, and BMI is 24 kg/m². Labs (4 months ago→today): Hb 13.9→13.4 g/dL; K 4.7→5.1 mEq/L; BUN 37→38 mg/dL; creatinine 1.8→2.0 mg/dL; albumin 3.9→4.0 g/dL; HbA1c 6.8%→6.7%; urine albumin-to-creatinine ratio 24→168 mg/g. What is the next best step in management?

  1. A.Prescribe semaglutide
  2. B.Measure 24-hour urinary albumin excretion
  3. C.Measure first-morning urine albumin-to-creatinine ratioCorrect
  4. D.Prescribe finerenone

Explanation

The next best step is to repeat the urine albumin-to-creatinine ratio on a first-morning sample. His albuminuria has risen from 24 to 168 mg/g in 4 months, but a single elevated value does not establish a change in albuminuria category. Day-to-day biological variability in albumin excretion is large, often 30% to 50% or more, and transient increases occur with vigorous exercise, fever, infection, marked hyperglycemia, heart failure, menstruation, and upright posture. He exercises regularly, and a random daytime specimen may reflect recent exertion. KDIGO 2024 recommends a first-morning void for albumin-to-creatinine ratio testing because it minimizes orthostatic and exercise effects and correlates best with 24-hour excretion, and advises confirming abnormal or changed results with repeat testing, with two of three samples over 3 to 6 months defining persistent albuminuria. Confirmation matters here because the result will determine whether to intensify therapy with a nonsteroidal mineralocorticoid receptor antagonist, which in his case is also constrained by a potassium that has risen to 5.1 mEq/L. A 24-hour urine collection for albumin is cumbersome, prone to collection error, and no more accurate in practice than a first-morning albumin-to-creatinine ratio, which KDIGO prefers. Finerenone reduced kidney and cardiovascular outcomes in FIDELIO-DKD and FIGARO-DKD in patients with type 2 diabetes and persistent albuminuria of at least 30 mg/g on maximal RAS blockade, but albuminuria must first be confirmed, and initiation is not recommended when potassium exceeds about 5.0 mEq/L. Semaglutide reduced major kidney events in FLOW and is reasonable for many patients with diabetic kidney disease, but his glycemic control is excellent with an HbA1c of 6.7% and a BMI of 24 kg/m², and the immediate question is whether his albuminuria has truly increased.

Why each option

A.
Semaglutide reduced kidney events in FLOW, but with HbA1c 6.7% and BMI 24 kg/m², confirming the albuminuria change is the more immediate step.
B.
A 24-hour collection is cumbersome and prone to error, and KDIGO prefers a first-morning albumin-to-creatinine ratio, which correlates well with 24-hour excretion.
C.
Correct. A single rise from 24 to 168 mg/g in a regular exerciser may be transient; KDIGO 2024 advises confirming with a repeat first-morning sample.
D.
Finerenone requires confirmed persistent albuminuria on RAS blockade, and initiation is not advised when potassium exceeds about 5.0 mEq/L, as his 5.1 does.

Reference: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD; Bakris GL, N Engl J Med 2020 (FIDELIO-DKD); Perkovic V, N Engl J Med 2024 (FLOW)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Diabetic Nephropathy questions

Browse other topics